+44 (0) 2036426654
info@pharmexcel-cro.com
Skip to content
About
People
Testimonials
Careers
Therapeutic Areas
Sectors
Biotech Solutions
ATMP studies
Services
Insights
News & Studies
Blogs
Case Studies
Events & Awards
Contact
PHARMExcel are pleased to announce their latest Lancet publication on Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters
Posted on
10th May 2022
Share this page